Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

ffective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market.  Amgen's business may be impacted by government investigations, litigation and products liability claims.  Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products.  In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products.  Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products.  In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or ma
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... quarter ended June 30, 2015 on Tuesday, August 4, ... Regulus will host a conference call and webcast ... Daylight Time to discuss its second quarter 2015 financial ...
(Date:7/28/2015)... -- Express Scripts Holding Company (Nasdaq: ESRX ) announced ... stockholders of $600.1 million, or $0.88 per diluted share.  ... 4, were $1.44 for the second quarter. 1  ... healthcare are validating the need for size and scale," ... what matters most is how that size and scale ...
(Date:7/28/2015)... 2015 On the afternoon of August 11, ... CPI International, Inc. (CPI), plans to file its Form ... with the Securities and Exchange Commission and to issue ...  At 11 a.m. (EDT) on Wednesday, August 12, 2015, ... with this release that will be Web cast simultaneously ...
Breaking Medicine Technology:Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25CPI International To Announce Third Quarter 2015 Financial Results 2
... to 50% of Patients and Was,Well-Tolerated ,PRINCETON, NJ, ... Network),-- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical,company ... from its completed Phase 2/3 study of liarozole,in ... 1 in 200,000) which is characterized by a ...
... Spain, June 15, 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squibb ... safety of ORENCIA(R) (abatacept) from the open-label,phase ... with juvenile,idiopathic arthritis (JIA) who have had ... anti- rheumatic drugs (DMARDs), such,as methotrexate (MTX) ...
Cached Medicine Technology:Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 2Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 3Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 4Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6
(Date:7/29/2015)... ... July 29, 2015 , ... For the second year in ... in the list of the 50 fastest growing companies in Jacksonville. This annual list ... community. On July 16th, a team of Vast Bridges staffers were on hand to ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... MD (PRWEB) , ... July 29, 2015 , ... A ... Get Checked for Skin Cancer ," discussed the importance of having regular skin cancer ... a person has excessive exposure to ultraviolet rays. When caught early, skin cancer is ...
(Date:7/29/2015)... ... , ... Several years ago, in order to be in the strongest position ... proactive stance and began planning the Children’s Village consisting of six homes. , Two ... the third home. , “We are very pleased to have received the $500,000 grant ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto native ... late 1970s, Dr. Cottrell has been making predictions about the economy, politics, social ... many of these prognostications. He warns that extreme weather conditions and increased earthquake ...
Breaking Medicine News(10 mins):Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
... Thomas Lescault, president of SCAN Long Term Care and ... the new Arizona Association of Health Plans. "The new ... providing accessible, affordable healthcare here in Arizona," said Lescault. ... the Arizona Legislature and the governor,s office in adjusting ...
... today by Every Child By Two:The U.S. Court of ... the causes of autism. The three judges ruled ... thimerosal-containing vaccines, does not cause autism. The ruling ... failed to show a link between vaccines and the ...
... don,t respond to current treatments, study finds , , ... shows promise against psoriatic arthritis (PA), according to a ... and North America. , PA affects about 11 percent ... the skin and joints. Some patients don,t respond to ...
... rhinoviruses now sequenced, could lead to new treatments, researchers ... medical breakthrough: a cure for the common cold. , ... a significant step in that direction: the genetic codes ... nasal infections. , "There has been brilliant work done ...
... Spencer Inc.,(NYSE: CSA ) announces the promotion ... the Company,s wholly owned subsidiary, Erdman, A Cogdell,Spencer Company ... Company,s Atlanta office, Ms. Dorr will focus on developing,and ... and development projects in the Region, which includes Georgia,Florida, ...
... N.J., Feb. 12 The Journal of Commerce Conferences, ... will take place May 12 and 13, 2009, at ... the event is "Linking Up the Cold Chain," and ... refrigerated and frozen cargo, will be the conference host.Cool ...
Cached Medicine News:Health News:SCAN's Thomas Lescault Elected President of New Arizona Association of Health Plans 2Health News:Federal Court Declares Vaccines Do Not Cause Autism 2Health News:Drug Reduces Inflammatory Arthritis Symptoms, Lesions 2Health News:Genetic Code of Common Cold Cracked 2Health News:Genetic Code of Common Cold Cracked 3Health News:Cogdell Spencer Announces Dorr as President of the Southeast Region 2Health News:Cogdell Spencer Announces Dorr as President of the Southeast Region 3Health News:'Linking Up the Cold Chain' is Focus of The JoC Conferences' First Cool Cargoes Conference, May 12-13, in Portland, Oregon 2Health News:'Linking Up the Cold Chain' is Focus of The JoC Conferences' First Cool Cargoes Conference, May 12-13, in Portland, Oregon 3
... St. Jude Medical is the world ... introducers are used worldwide for permanent ... venous catheter and port implantation, and ... design of St. Jude Medical Peel-Away ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... The OMNILINK®.035 Biliary Stent System is a supportive .035" ... 5.0 - 10.0 mm in lengths of 18 mm, ... - 7.0 mm diameters available in 12 and 16 ... available in 18mm lengths. Two "diameter specific" OMNILINK® ...
Medicine Products: